LENZ Therapeutics Debuts With $47 Million Series A Financing
SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, a biopharmaceutical company with a lead late clinical-stage program that represents a potential best-in-class therapy for presbyopia, today emerged from stealth mode with a $47 million Series A financing from Versant Ventures and RA Capital Management. Proceeds from the financing will be utilized to progress the company’s lead asset, an eyedrop formulation of aceclidine, towards an NDA submission for the treatment of presbyopia. Presbyopia impacts